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Patients with chronic obstructive pulmonary disease (COPD) have a high risk of mortal-
ity after acute ST-segment elevation myocardial infarction (STEMI). We compared STEMI
patients with versus without COPD in terms of infarct size and left ventricular (LV) sys-
tolic function using advanced 2-dimensional speckle tracking echocardiography. Of 1,750
patients with STEMI (mean age 61 ± 12 years, 76% male), 133 (7.6%) had COPD. With
transthoracic echocardiography, left ventricular ejection fraction (LVEF) and wall motion
score index were measured. Infarct size was assessed using biomarkers (creatine kinase and
troponin T). LV global longitudinal strain (GLS), reflecting active LV myocardial defor-
mation, was measured with 2-dimensional speckle tracking echocardiography to estimate
LV systolic function and infarct size. STEMI patients with COPD were significantly older,
more likely to be former smokers, and had worse renal function compared with patients
without COPD. There were no differences in infarct size based on peak levels of creatine
kinase (1315 [613 to 2181] vs 1477 [682 to 3047] U/l, p = 0.106) and troponin T (3.3 [1.4 to
7.3] vs 3.9 [1.5 to 7.8] µg/l, p = 0.489). Left ventricular ejection fraction (46% vs 47%, p = 0.591)
and wall motion score index (1.38 [1.25 to 1.66] vs 1.38 [1.19 to 1.69], p = 0.690) were com-
parable. In contrast, LV GLS was significantly more impaired in patients with COPD
compared with patients without COPD (−13.9 ± 3.0% vs −14.7 ± 3.9%, p = 0.034). In con-
clusion, despite comparable myocardial infarct size and LV systolic function as assessed
with biomarkers and conventional echocardiography, patients with COPD exhibit more im-
paired LV GLS on advanced echocardiography than patients without COPD, suggesting a
greater functional impairment at an early stage after STEMI. © 2017 The Author(s).
Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2017;120:734–739)
Patients with chronic obstructive pulmonary disease
(COPD) who present with ST-segment elevation myocar-
dial infarction (STEMI) have higher in-hospital and 6-month
mortality rates compared with patients without COPD.1–3 Pos-
sible mechanisms underlying this worse prognosis in patients
with COPD include poor recognition and management of myo-
cardial infarction, underutilization of secondary prevention
therapies, and pathophysiological factors related to COPD (i.e.
chronic inflammation).3,4 These factors may result in larger
infarct size and worse left ventricular (LV) systolic func-
tion. However, it remains unknown whether STEMI patients
with COPD differ from patients without COPD in terms of
infarct size and LV systolic function acutely after STEMI.
LV ejection fraction (EF) and wall motion score index (WMSI)
are commonly used in clinical practice to estimate LV sys-
tolic function and for risk stratification of patients with
STEMI.5,6 However, these conventional echocardiographic pa-
rameters may not be sensitive enough to characterize the extent
of myocardial damage after STEMI.7,8 Two-dimensional (2D)
speckle tracking echocardiography global longitudinal strain
(GLS), reflecting active deformation of the LV myocar-
dium, has emerged as a valuable index of LV systolic function
and infarct size.9 The present study aimed at evaluating the
differences in infarct size and systolic function in STEMI pa-
tients with versus without COPD by measuring biomarkers
(creatine kinase [CK] and troponin T) as well as conven-
tional and advanced 2D speckle tracking echocardiography.
Methods
Of an ongoing registry of patients admitted with acute STEMI
and treated with primary percutaneous coronary intervention
(PCI) at the Leiden University Medical Centre (Leiden, The
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Netherlands), patients with complete echocardiographic data at
baseline (within 48 hours of admission) were included
(Figure 1).10 Patients were managed according to the most recent
American College of Cardiology/American Heart Association
and European Society of Cardiology guidelines.6,11 This in-
cludes systematic measurements of CK and troponin T and
transthoracic echocardiography within 48 hours of admission.
Clinical and echocardiographic data were prospectively col-
lected at the departmental Cardiology Information System (EPD-
vision, Leiden University Medical Centre) and echocardiography
database, respectively, and analyzed retrospectively. For this ret-
rospective analysis of clinically acquired data, the institutional
review board waived the need for patient written informed
consent.
Patient demographic and clinical characteristics were re-
corded. Hypertension was defined as a systolic blood pressure
>140 mm Hg or diastolic blood pressure >90 mm Hg, or pre-
vious use of antihypertensive drugs. Hypercholesterolemia was
defined as having a recorded history of hypercholesterolemia
and/or use of statins. Diabetes mellitus was defined as having
a history of diabetes and subsequent treatment with a diet, oral
glucose-lowering agents, or insulin. Killip class was regis-
tered at admission.12 During invasive coronary angiography, the
culprit vessel was identified and multivessel disease was defined
as more than 1 vessel with >50% luminal stenosis.
COPD was defined as having a documented history of
COPD at admission, after reviewing the entire medical record.
When available, pulmonary function tests were considered,
and COPD was diagnosed if the ratio of forced expiratory
volume in one second to forced vital capacity ratio was <0.7.13
The use of this definition of COPD, when systematic pul-
monary function tests are not available, is in line with previous
studies.1,2,14–16 Patients with a recorded history of asthma were
listed as non-COPD, given the different pathophysiology.13
Images were obtained with the patient at rest, in left lateral
decubitus position using a commercially available system
(Vivid 7 and E9, GE Healthcare, Horten, Norway). Stan-
dard 2D images were obtained from the parasternal (long-
and short-axis) and apical (long-axis, 2- and 4-chamber) views,
using 3.5-MHz or M5S transducers, and digitally stored in
cine-loop format. Furthermore, color, pulsed, and continu-
ous wave Doppler images were acquired. Offline analysis of
the obtained images was performed using EchoPAC (version
BT13, GE Medical Systems, Horten, Norway).
Left ventricular diameters and wall thickness were mea-
sured in the parasternal long-axis view. Subsequently, LV mass
was calculated using the Devereux’s formula and indexed for
body surface area.5 Left ventricular end-systolic and end-
diastolic volumes were measured in apical 4- and 2-chamber
views and left ventricular ejection fraction (LVEF) was calcu-
lated using the biplane Simpson’s method.5 For calculation of
the WMSI, the LV was divided into 16 segments. Each segment
was assessed and scored based on its motion and systolic thick-
ening (1 = normokinesia, 2 = hypokinesia, 3 = akinesia,
4 = dyskinesia). The WMSI was calculated as the sum of the
individual segment scores divided by the number of segments.5
Left ventricular diastolic function was assessed based on peak
velocity of the early diastolic filling (E-wave) and late filling
by atrial contraction (A-wave), together with E-wave decelera-
tion time obtained on the pulsed-wave Doppler recordings of
the transmitral flow, the left atrial volume, and pulmonary sys-
tolic pressures estimated from the tricuspid regurgitation peak
velocity on continuous wave Doppler recordings.17
For evaluation of LV GLS, 2D speckle tracking analysis was
performed as previously described.18 In brief, the LV endocar-
dial border was traced at an end-systolic frame in the apical long-
axis, 2-and 4-chamber views. The automatically created region
of interest was manually adjusted to the thickness of the myo-
cardium. Thereafter, the myocardium was automatically tracked
throughout the cardiac cycle. LV GLS was calculated by the
software as the average of the peak systolic strain of the three
apical views, and presented in a 17-segment “bull’s-eye” plot.
The inter- and intraobserver variability of LV GLS measure-
ments have been previously reported as mean absolute difference
of 1.2 ± 0.5% and 0.9 ± 1.0%, respectively.19
Statistical analyses were performed using SPSS software
(version 23, IBM SPSS statistics for Windows, Armonk, New
York). Continuous variables are presented as mean ± standard
Figure 1. Flowchart of patient selection and enrollment for analysis. aPatients with STEMI were admitted between February 2004 and May 2013.
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deviation when normally distributed, and median and interquartile
range otherwise. Categorical variables are presented as fre-
quencies and percentages. Differences in continuous variables
between patients with and without COPD were analyzed using
the unpaired Student’s t test or Mann-Whitney U-test as ap-
propriate. Categorical variables were compared using the chi-
square test or Fisher’s exact test as appropriate. A 2-tailed p value
of <0.05 was considered statistically significant.
Results
Of 1,750 patients with STEMI, 133 patients (7.6%) had
a history of COPD. The clinical characteristics of the pa-
tients with and without COPD are presented in Table 1.
Compared with patients without COPD, patients with COPD
were significantly older, more likely to be former smokers,
and had a higher prevalence of previous myocardial infarc-
tion. In addition, patients with COPD had a significantly worse
kidney function and presented more frequently with heart
failure. Guideline-based medical therapy at discharge was
similar in groups, except for β-blockers, which were less fre-
quently prescribed in patients with COPD compared with
patients without COPD (89% and 95%, p = 0.011).
There were no statistically significant differences in pa-
tients with and without COPD in terms of infarct size based
on peak levels of CK (1315 [613 to 2181] vs 1477 [682 to
3047] U/l, p = 0.106, respectively) and troponin T (3.3 [1.4
to 7.3] vs 3.9 [1.5 to 7.8] µg/l, p = 0.489, respectively).
Echocardiographic characteristics of the patients with and
without COPD are presented in Table 2. Compared with pa-
tients without COPD, patients with COPD had significantly
smaller LV dimensions. LVEF was similar in both patients
with and without COPD (46 ± 10% and 47 ± 9%, respec-
tively, p = 0.591). In addition, the WMSI was 1.38 [1.25 to
1.66] for patients with COPD and 1.38 [1.19 to 1.69] for
patients without COPD, p = 0.690. However, LV GLS was
significantly more impaired in patients with COPD com-
pared with patients without COPD (−13.9 ± 3.0% and
−14.7 ± 3.9%, p = 0.034), indicating more reduced systolic
LV function and larger area of infarction in the patients with
Table 1
Clinical characteristics
Variable COPD p value
Yes (N = 133) No (N = 1617)
Age (years) 69 ± 11 60 ± 12 <0.001
Men 97 (73%) 1229 (76%) 0.427
Systolic blood pressure (mmHg) 140 [120–160] 135 [120–150] 0.096
Diastolic blood pressure (mmHg) 84 ± 18 81 ± 16 0.071
Heart rate (beats/min) 73 ± 16 74 ± 18 0.709
Body mass index (kg/m2) 25.7 [24–29] 26.0 [24–28] 0.502
Killip class 0.045
<2 121 (92%) 1539 (96%)
≥2 11 (8%) 72 (4%)
Diabetes mellitus 19 (14%) 168 (10%) 0.163
Hypertension 54 (41%) 569 (35%) 0.226
Hypercholesterolemia 27 (21%) 325 (20%) 0.879
Family history of cardiovascular disease 47 (37%) 705 (44%) 0.133
Current smoker 68 (51%) 764 (47%) 0.396
Ex-smoker 23 (17%) 173 (11%) 0.021
Previous myocardial infarction 12 (9%) 47 (3%) <0.001
Culprit coronary artery 0.389
Left anterior descending 49 (37%) 721 (45%)
Right coronary artery 55 (42%) 618 (38%)
Circumflex coronary artery 26 (20%) 258 (16%)
Left main 1 (1%) 10 (1%)
Number of diseased vessels 0.225
1 61 (46%) 751 (47%)
2 31 (24%) 555 (35%)
3 39 (30%) 304 (19%)
Peak creatinine kinase (U/L) 1316 [613–2183] 1477 [682–3047] 0.106
Peak troponin T (µg/L) 3.3 [1.4–7.3] 3.9 [1.5–7.8] 0.489
Glucose (mmol/L) 7.5 [6.3–9.8] 8.0 [6.6–9.7] 0.223
Creatinine clearance (ml/min/1.73 m2) 84 ± 33 99 ± 37 <0.001
Medication at discharge
β-blocker 114 (89%) 1507 (95%) 0.011
ACE inhibitor or angiotensin-II receptor blocker 124 (98%) 1555 (98%) 1.000
Aspirin 124 (97%) 1530 (96%) 0.814
Thienopyridines* 127 (99%) 1587 (100%) 0.462
Statin 128 (100%) 1581 (99%) 0.616
COPD = chronic obstructive pulmonary disease. Continuous variables are presented as mean ± standard deviation or median [25th to 75th percentile]. *Clopidogrel
or prasugrel.
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COPD despite similar infarct size according to enzyme release
(biomarkers). Figure 2 presents a more impaired LV GLS in
a STEMI patient with COPD compared with a patient without
COPD, with comparable LVEF, WMSI, and infarct size based
on peak levels of CK and troponin T.
Discussion
The present study demonstrates that STEMI patients with
concomitant COPD have more impaired LV systolic func-
tion and larger infarct area based on LV GLS compared with
patients without COPD, despite having similar infarct size
as assessed with cardiac biomarkers. These findings suggest
that STEMI patients with COPD have greater impairment of
LV systolic function at an early stage after STEMI. LVEF
and WMSI may not be sensitive enough to detect this im-
pairment of LV systolic function.
Infarct size is an important prognostic marker after STEMI.20
Creatine kinase and troponin levels and imaging modalities, in-
cluding echocardiography, nuclear imaging techniques, and late
gadolinium contrast-enhanced cardiac magnetic resonance, are
well-established methods to estimate the infarct size.21 Whether
the presence of COPD has influence on infarct size has not been
extensively evaluated.22,23 In 818 patients with STEMI (8.6%
with COPD), Lazzeri et al showed no significant differences
in peak troponin I in patients with and without COPD (54.1 [28.7
to 212] vs 92.2 [44.1 to 186.0] ng/ml, p = 0.084, respectively).22
Similar results were demonstrated by Wakabayashi et al in 365
STEMI patients with COPD compared with 2,884 patients
without COPD (peak CK-MB 59.0 ± 93.2 ng/ml vs
63.5 ± 97.2 ng/ml, p = 0.4, respectively).23 The present study pro-
vides additional information by providing echocardiographic
estimates of infarct size. LVEF and WMSI measured on
echocardiography have been shown to correlate with infarct
size.20,24 Particularly, WMSI may reflect infarct size better than
LVEF.25 In this large cohort of patients, LVEF and WMSI were
not significantly different between STEMI patients with COPD
and patients without COPD, suggesting that both groups of pa-
tients have comparable myocardial damage based on these
conventional echocardiographic parameters.
Although LVEF and WMSI are routine echocardiographic
parameters measured in patients with STEMI to estimate LV
systolic function and for risk stratification, the advent of
speckle tracking echocardiography (which measures LV strain,
deformation of the LV myocardium) has permitted obtain-
ing more sensitive parameters of LV systolic function and better
reflectors of myocardial damage.24,26 Both global and re-
gional longitudinal strain have shown to be accurate in
evaluating global LV function and the presence of segments
with transmural necrosis using cardiac magnetic resonance
as a reference.27 In addition, using single-photon emission com-
puted tomography myocardial perfusion imaging as reference,
LV GLS has demonstrated to be superior to LVEF in pre-
dicting the infarct size at 30-day follow-up.26
In the present study, STEMI patients with COPD showed more
impaired LV GLS compared with patients without COPD, despite
having similar levels of biomarkers and comparable values of
conventional echocardiographic parameters of LV systolic func-
tion. These results suggest that STEMI patients with COPD have
larger myocardial damage than patients without COPD. There-
fore, measuring LV GLS in the acute phase of STEMI may be
a better marker of true myocardial damage in patients with COPD
than conventional echocardiographic parameters and may be a
more sensitive parameter for risk stratification of these pa-
tients. The underlying mechanisms explaining worse LV GLS
as a reflection of larger infarct size in patients with COPD may
relate to the chronic inflammatory status of patients with COPD.
The severity of the airflow obstruction has been shown to in-
fluence the inflammatory status, and patients with severe COPD
have shown higher levels of C-reactive protein and higher cardiac
infarction injury score compared with patients without airflow
obstruction.28 In addition, systemic inflammation has been linked
to reperfusion injury, causing larger myocardial infarct size.29
Future research is needed to elaborate this physiopathology.
Table 2
Echocardiographic characteristics
Variable COPD p value
Yes (n = 133) No (n = 1617)
LV end-diastolic diameter (mm) 46 ± 7 48 ± 6 0.001
LV end-systolic diameter (mm) 30 [26–37] 32 [27–37] 0.101
Posterior wall thickness (mm) 12 ± 2.2 11 ± 2.1 0.031
Interventricular septum thickness (mm) 11 [10–13] 11 [10–13] 0.181
LV mass (g) 203 ± 75 212 ± 66 0.134
Indexed LV mass (g/m2) 104 ± 34 108 ± 30 0.171
LV end-systolic volume (mL) 48 [39–61] 53 [42–68] 0.012
LV end-diastolic volume (mL) 92 [74–116] 101 [82–123] 0.009
Wall motion score index 1.38 [1.25–1.66] 1.38 [1.19–1.69] 0.690
LV ejection fraction (%) 46 ± 10 47 ± 9 0.591
LV global longitudinal strain (%) −13.9 ± 3.9 −14.7 ± 3.9 0.034
E-wave peak velocity (cm/s) 66 ± 18 66 ± 19 0.885
A-wave peak velocity (cm/s) 76 ± 21 71 ± 24 0.051
E/A ratio 0.84 [0.69–1.06] 0.91 [0.72–1.14] 0.039
E-wave deceleration time (ms) 215 ± 85 210 ± 72 0.638
COPD = chronic obstructive pulmonary disease; LV = left ventricle. Continuous variables are presented as mean ± standard deviation or median [25th to
75th percentile].
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Several study limitations should be acknowledged. First,
this is a single centre, retrospective study that cannot provide
causal relations. Second, the presence or absence of COPD
in the study population was solely based on patients’ medical
records as pulmonary functional tests were not systemati-
cally available. However, we did find a similar prevalence of
COPD in our population compared with the existing studies
in the literature, which used the same definition of COPD.1,14
In addition, without pulmonary functional tests, we were not
able to classify the severity of COPD.
In conclusion, STEMI patients with and without COPD have
comparable myocardial infarct size and LV systolic function as
assessed with biomarkers and conventional echocardiography,
respectively. However, patients with COPD exhibit more im-
paired LV GLS than their counterparts, suggesting more
myocardial damage and worse LV systolic function in the early
phase after STEMI in patients with COPD.
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Figure 2. Bull’s-eye plot of left ventricular (LV) global longitudinal strain (GLS) assessed by speckle tracking echocardiography. (A) STEMI patient with
COPD (culprit vessel RCA), with LVEF 48% (comparable with patient B without COPD). LV GLS was more impaired (less negative) than in patient B without
COPD, −11.7% vs −17.5%, respectively. (B) STEMI patient without COPD (culprit vessel RCA) with LVEF 47%. Biomarkers for infarct size (CK and tro-
ponin) were similar in both patients. Arrows indicate the infarct location. ANT = anterior; ANT_SEPT = anteroseptal; CK = creatine phosphokinase; INF = inferior;
LAT = lateral; LVEF = left ventricular ejection fraction; POST = posterior; RCA = ramus descendens anterior; SEPT = septal; WMSI = wall motion score index.
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